MCL1 and neoplasm: Immunoblotting of tumor tissues revealed that treatment with apigenin or a combination of apigenin and ABT‐263 resulted in decreased expression of Mcl‐1 and reduced phosphorylation of AKT and ERK, suggesting that apigenin can also target these pro‐survival modulators in vivo (Shao et al., 2013).